| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18786266 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 103 journal articles in the PubMed database | Email to a friend | | |
| Laterre PF, Macias WL, Janes J, et al.
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. [JOURNAL ARTICLE]
Crit Care 2008 Sep 11; 12(5):R117.
Abstract | Full Citation | Find Related Articles | | Vincent JL, O'brien J, Wheeler A, et al.
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. [JOURNAL ARTICLE]
Crit Care 2006 May 9; 10(3):R74.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Wheeler A, Steingrub J, Schmidt GA, et al.
A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. [JOURNAL ARTICLE]
Crit Care Med 2008 Jan; 36(1):14-23.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Laterre PF, Garber G, Levy H, et al.
Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. [Journal Article]
Crit Care Med 2005 May; 33(5):952-61.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cobas Meyer M, Langenfeld H, Rossaint R, et al.
[PROWESS, ENHANCE and ADDRESS : Clinical implications for the treatment with drotrecogin alfa (activated).] [JOURNAL ARTICLE]
Anaesthesist 2006 May 6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Green C, Dinnes J, Takeda A, et al.
Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. [Clinical Trial, Journal Article, Randomized Controlled Trial]
Health Technol Assess 2005 Mar; 9(11):1-126, iii-iv.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Short MA, Schlichting D, Qualy RL
From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated). [Journal Article]
Curr Med Res Opin 2006 Dec; 22(12):2525-40.
Full Citation | Find Related Articles | | Bernard GR, Margolis BD, Shanies HM, et al.
Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. [Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study]
Chest 2004 Jun; 125(6):2206-16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Dhainaut JF, Laterre PF, LaRosa SP, et al.
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. [Clinical Trial, Clinical Trial, Phase III, Evaluation Studies, Journal Article, Multicenter Study, Randomized Controlled Trial]
Crit Care Med 2003 Sep; 31(9):2291-301.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
